Back to Menu
1. Clinical presentation assessment
A detailed history is obtained regarding hematuria characteristics and irritative voiding symptoms, and physical examination assesses potential local invasion.
2. Urine testing
Urinalysis evaluates microscopic hematuria; urine cytology detects malignant cells; novel biomarkers may improve early detection rates.
3. Cystoscopy
The diagnostic gold standard. It allows direct visualization of lesions and targeted biopsy to determine histologic type and grade.
4. Imaging examinations
Ultrasonography can identify masses, while CT urography evaluates depth of invasion and lymph node involvement.
5. Pathological diagnosis
Histopathology from biopsy or surgical specimens defines histologic subtype and grade and determines the treatment strategy.
6. Urography
Intravenous urography can demonstrate filling defects and helps assess whether the upper urinary tract is involved.
7. Tumor marker testing
Urine- and blood-based biomarkers are used as adjuncts for diagnosis and for surveillance during follow-up.
8. Staging assessment
TNM staging evaluates invasion depth and metastatic status, guiding treatment selection and prognostic estimation.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that bladder cancer is a common urinary tract malignancy. Early symptoms are often atypical and easily overlooked, and some patients may already have intermediate-to-advanced disease at diagnosis. Vigilance for painless hematuria is essential. High-risk individuals should undergo regular screening and seek timely medical evaluation for definitive diagnosis. Early detection with standardized treatment can markedly improve outcomes, and MDT-based collaboration enhances diagnostic and therapeutic effectiveness.
1. Clinical presentation assessment
A detailed history is obtained regarding hematuria characteristics and irritative voiding symptoms, and physical examination assesses potential local invasion.
2. Urine testing
Urinalysis evaluates microscopic hematuria; urine cytology detects malignant cells; novel biomarkers may improve early detection rates.
3. Cystoscopy
The diagnostic gold standard. It allows direct visualization of lesions and targeted biopsy to determine histologic type and grade.
4. Imaging examinations
Ultrasonography can identify masses, while CT urography evaluates depth of invasion and lymph node involvement.
5. Pathological diagnosis
Histopathology from biopsy or surgical specimens defines histologic subtype and grade and determines the treatment strategy.
6. Urography
Intravenous urography can demonstrate filling defects and helps assess whether the upper urinary tract is involved.
7. Tumor marker testing
Urine- and blood-based biomarkers are used as adjuncts for diagnosis and for surveillance during follow-up.
8. Staging assessment
TNM staging evaluates invasion depth and metastatic status, guiding treatment selection and prognostic estimation.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that bladder cancer is a common urinary tract malignancy. Early symptoms are often atypical and easily overlooked, and some patients may already have intermediate-to-advanced disease at diagnosis. Vigilance for painless hematuria is essential. High-risk individuals should undergo regular screening and seek timely medical evaluation for definitive diagnosis. Early detection with standardized treatment can markedly improve outcomes, and MDT-based collaboration enhances diagnostic and therapeutic effectiveness.